Pharmacologic class: Proteasome inhibitor
Therapeutic class: Antineoplastic
Pregnancy risk category D
Inhibits proteasomes (enzyme complexes that regulate protein homeostasis within cells). Reversibly inhibits chymotrypsin-like activity at 26S proteasome, leading to activation of signaling cascades, cell-cycle arrest, and apoptosis.
Powder for reconstitution (preservative-free): 3.5 mg (contains 35 mg of mannitol)
Indications and dosages
➣ Multiple myeloma, patients with mantle cell lymphoma who have received at least one prior therapy
Adults: 1.3 mg/m2 I.V. or subcutaneously twice weekly for 2 weeks (days 1, 4, 8, and 11), followed by 10-day rest period (days 12 to 21). Allow at least 72 hours to elapse
between doses. One treatment cycle equals 21 days (3 weeks).
• Moderate or severe hepatic impairment
• Peripheral neuropathy
• Grade 3 nonhematologic events
• Grade 4 hematologic events
• Hypersensitivity to drug, mannitol, or boron
Use cautiously in:
• peripheral neuropathy, dehydration, hepatic or renal impairment
• history of syncope or cardiovascular disorders
• pregnant or breastfeeding patients
• Be aware that drug is for I.V. or subcutaneous use only. Because each route of administration has a different reconstituted concentration, use caution when calculating volume to be administered.
• Reconstitute drug in vial with 3.5 ml of normal saline for injection to yield a concentration of 1 mg/ml for I.V. use.
• Reconstitute drug in vial with 1.4 ml of normal saline for injection to yield a concentration of 2.5 mg/ml for subcutaneous use.
• Give by I.V. push over 3 to 5 seconds or subcutaneously.
• Reconstituted solution must be used within 8 hours.
CNS: headache, insomnia, dizziness, anxiety, peripheral neuropathy, reversible posterior leukoen-cephalopathy syndrome
CV: tachycardia, hypotension
EENT: throat tightness
GI: nausea, vomiting, diarrhea, abdominal pain, dyspepsia
Hematologic: eosinophilia, anemia, thrombocytopenia, neutropenia
Hepatic: hyperbilirubinemia, hepatitis, acute liver failure
Metabolic: dehydration, pyrexia
Respiratory: cough, dyspnea, upper respiratory tract infection, acute diffuse infiltrative pulmonary disease (pneumonitis, interstitial pneumonia, acute respiratory distress syndrome)
Skin: rash, pruritus, urticaria
Other: altered taste, increased or decreased appetite, fever, chills, edema, tumor lysis syndrome
Drug-drug. CYP3A4 inducers (including amiodarone, carbamazepine, nevi-rapine, phenobarbital, phenytoin, and rifampin): possible decrease in bortezomid serum level and efficacy
CYP3A4 inhibitors (including amiodarone, cimetidine, clarithromycin, delavirdine, diltiazem, disulfiram, erythromycin, fluoxetine, fluvoxamine, nefazodone, nevirapine, propoxyphene, quinupristin, verapamil, zafirlukast, and zileuton): possible increase in bortezomib serum level and efficacy
Drug-diagnostic tests. Liver function
tests: increased levels
Drug-food. Grapefruit juice: increased bortezomib blood level, greater risk of toxicity
☞ Monitor vital signs and temperature. Especially watch for tachycardia, fever, and hypotension.
☞ Stay alert for and discontinue drug if posterior leukoencephalopathy (headache, seizures, lethargy, confusion, blindness) or tumor lysis syndrome occurs (irregular heartbeat, shortness of breath, high potassium level, high uric acid level, impairment of mental ability, kidney failure).
☞ Closely monitor liver function tests and watch for signs and symptoms of hepatitis or liver failure.
• Monitor nutritional and hydration status for changes caused by GI adverse effects.
• Monitor CBC with white cell differential, and watch for signs and symptoms of blood dyscrasias.
☞ Monitor respiratory status, watching for dyspnea, cough, and other signs and symptoms of upper respiratory tract infection.
☞ Inform patient that drug can cause serious blood dyscrasias. Teach him which signs and symptoms to report right away.
• Tell patient that drug may cause other significant adverse reactions. Reassure him he will be closely monitored.
• Instruct patient to move slowly when sitting or standing up to avoid dizziness or light-headedness from sudden blood pressure drop.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• Advise patient to minimize adverse GI effects by eating small frequent servings of healthy food and ensuring adequate fluid intake.
• Tell patient to immediately report signs and symptoms of upper respiratory tract infection.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and foods mentioned above.
bortezomibA proteasome inhibitor which induces apoptosis in cancer cells, and inhibits binding to stromal cells and production of growth and survival factors.
Treatment-refractory myeloma (35% response rate), mantle cell lymphoma.
Thrombocytopaenia, fatigue, peripheral neuropathy, neutropaenia.
VelcadeA brand name for BORTEZOMIB.
Patient discussion about Velcade
Q. Has anyone out there taken the new drug Velcade?????? I've just started a JNJ Valcade trial and wonder if anyone out there has any experience this chemo treatment.